Showing results (1-10 of 34) with videos related to
Sort By:
Pageof 4
Journal of Electrocardiology|May 11, 2004
A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessmentJoel MorganrothDrug Safety|May 27, 2015
Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/BenefitRashmi R Shah, Joel MorganrothDrug Safety|August 1, 2012
Early investigation of QTc liability: the role of multiple ascending dose (MAD) studyRashmi R Shah, Joel MorganrothBritish Journal of Clinical Pharmacology|August 22, 2012
ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studiesRashmi R Shah, Joel MorganrothCOPD|December 2, 2006
Eletrocardiographic monitoring in COPD patients receiving tiotropiumJoel Morganroth, Wolfgang Golisch, Steven KestenTherapeutic Innovation & Regulatory Science|September 22, 2018
Benefits of Centralized ECG Reading in Clinical Oncology StudiesRobert Kleiman, Jeffrey Litwin, Joel MorganrothThe Journal of Invasive Cardiology|November 5, 2013
Electrocardiographic response to intravenous and intraarterial injection of iosimenol (a new, iodinated, non-ionic, iso-osmolar contrast medium)James J Zhang, Joel Morganroth, Barry HogstromDrug Safety|April 27, 2013
Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacyDevron R Shah, Rashmi R Shah, Joel MorganrothDrug Safety|April 27, 2013
Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectivesRashmi R Shah, Joel Morganroth, Devron R ShahJournal of Clinical Pharmacology|May 23, 2002
Electrocardiographic effects of rivastigmineJoel Morganroth, Stephen Graham, Richard Hartman, et al.Pageof 4